KeithMGottesdienerMDFACP

Infectious Disease • Boston, MA

CEO, Rhythm Pharmaceuticals

Join to view full profile

Dr. Gottesdiener is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gottesdiener's full profile

Already have an account?

Office
Rhythm Pharmaceuticals
855 Boylston Street, 11th Floor
Boston, MA 02116
Phone+1 857-264-4280

Education & Training

Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1985 - 1988
Brigham and Women's HospitalResidency, Internal Medicine, 1982 - 1985
Perelman School of Medicine at the University of PennsylvaniaClass of 1982

Certifications & Licensure

NY State Medical License 1988 - 2026
CT State Medical License 1985 - 2025
MA State Medical License 1984 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Publications & Presentations

PubMed

1322 citations
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Susan Buchbinder, Devan V. Mehrotra, Ann Duerr, Daniel W. Fitzgerald, Robin Mogg
Lancet. 2008-11-29
47 citations
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis
Savino Bruno, John M. Vierling, Rafael Esteban, L. Nyberg, Hugo Tanno
Journal of Hepatology. 2013-03-01
231 citations
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor
H. Donald Burns, Koen Van Laere, Sandra M. Sanabria-Bohórquez, Terence G. Hamill, Guy Bormans
Proceedings of the National Academy of Sciences of the United States of America. 2007-06-05

Press Mentions

Prime Medicine Appoints Ann L. Lee as Chief Technical OfficerOctober 13th, 2021
Chutes & Ladders—Biogen CFO Capello Steps down from Role Amid M&A SpeculationJuly 24th, 2020
A Wobbly Biogen Makes a Surprise Switch in the Executive Suite, Triggering a Renewed Burst of M&A ChatterJuly 22nd, 2020
Join now to see all